{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:50:39Z","timestamp":1792723839575,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":2440,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1038\/mt.2009.231","type":"journal-article","created":{"date-parts":[[2009,10,6]],"date-time":"2009-10-06T14:00:46Z","timestamp":1254837646000},"page":"275-284","source":"Crossref","is-referenced-by-count":82,"title":["Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Jennifer","family":"Altomonte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Marozin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland M","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2009.231_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","article-title":"Estimating the world cancer burden: Globocan 2000","volume":"94","author":"Parkin","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2009.231_bib2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199903113401001","article-title":"Rising incidence of hepatocellular carcinoma in the United States","volume":"340","author":"El-Serag","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2009.231_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2036.2005.02504.x","article-title":"Review article: the changing epidemiology of hepatocellular carcinoma in Canada","volume":"22","author":"Dyer","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1038\/mt.2009.231_bib4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-139-10-200311180-00009","article-title":"The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update","volume":"139","author":"El-Serag","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1038\/mt.2009.231_bib5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(05)78179-4","article-title":"Trends in primary liver cancer","volume":"351","author":"Deuffic","year":"1998","journal-title":"Lancet"},{"key":"10.1038\/mt.2009.231_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2036.1998.00286.x","article-title":"Review article: overview of medical treatments in unresectable hepatocellular carcinoma\u2014an impossible meta-analysis?","volume":"12","author":"Mathurin","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1038\/mt.2009.231_bib7","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"10.1038\/mt.2009.231_bib8","first-page":"6017","article-title":"Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy","volume":"54","author":"Lorence","year":"1994","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2009.231_bib9","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.V98.7.2002","article-title":"Systemic therapy of myeloma xenografts by an attenuated measles virus","volume":"98","author":"Peng","year":"2001","journal-title":"Blood"},{"key":"10.1038\/mt.2009.231_bib10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat Med"},{"key":"10.1038\/mt.2009.231_bib11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0022-4804(92)90310-V","article-title":"Newcastle disease virus selectively kills human tumor cells","volume":"52","author":"Reichard","year":"1992","journal-title":"J Surg Res"},{"key":"10.1038\/mt.2009.231_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/713803696","article-title":"Vesicular stomatitis virus (VSV) therapy of tumors","volume":"50","author":"Balachandran","year":"2000","journal-title":"IUBMB Life"},{"key":"10.1038\/mt.2009.231_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1038\/mt.2009.231_bib14","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1128\/JVI.77.17.9522-9532.2003","article-title":"Newcastle disease virus V protein is a determinant of host range restriction","volume":"77","author":"Park","year":"2003","journal-title":"J Virol"},{"key":"10.1038\/mt.2009.231_bib15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-06-1817","article-title":"An optimized clinical regimen for the oncolytic virus PV701","volume":"13","author":"Hotte","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2009.231_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","article-title":"Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme","volume":"13","author":"Freeman","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2009.231_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/B:NEON.0000021735.85511.05","article-title":"MTH-68\/H oncolytic viral treatment in human high-grade gliomas","volume":"67","author":"Csatary","year":"2004","journal-title":"J Neurooncol"},{"key":"10.1038\/mt.2009.231_bib18","first-page":"1483","article-title":"Live viruses in cancer treatment","volume":"16","author":"Nemunaitis","year":"2002","journal-title":"Oncology (Williston Park, NY)"},{"key":"10.1038\/mt.2009.231_bib19","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1158\/0008-5472.CAN-07-1025","article-title":"Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus","volume":"67","author":"Vigil","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2009.231_bib20","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/sj.gt.3303026","article-title":"Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy","volume":"14","author":"Janke","year":"2007","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2009.231_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1993.1561","article-title":"Paramyxovirus fusion: a hypothesis for changes","volume":"197","author":"Lamb","year":"1993","journal-title":"Virology"},{"key":"10.1038\/mt.2009.231_bib22","first-page":"6566","article-title":"Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells","volume":"62","author":"Bateman","year":"2002","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2009.231_bib23","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1128\/JVI.74.11.5101-5107.2000","article-title":"A single amino acid change in the Newcastle disease virus fusion protein alters the requirement for HN protein in fusion","volume":"74","author":"Sergel","year":"2000","journal-title":"J Virol"},{"key":"10.1038\/mt.2009.231_bib24","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1128\/JVI.79.2.1180-1190.2005","article-title":"Decreased dependence on receptor recognition for the fusion promotion activity of L289A-mutated Newcastle disease virus fusion protein correlates with a monoclonal antibody-detected conformational change","volume":"79","author":"Li","year":"2005","journal-title":"J Virol"},{"key":"10.1038\/mt.2009.231_bib25","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1158\/0008-5472.CAN-03-3753","article-title":"Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer","volume":"64","author":"Ebert","year":"2004","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2009.231_bib26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.otohns.2006.11.046","article-title":"Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas","volume":"136","author":"Shin","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1038\/mt.2009.231_bib27","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/0042-6822(91)90420-G","article-title":"Identification of endoprotease activity in the trans Golgi membranes of rat liver cells that specifically processes in vitro the fusion glycoprotein precursor of virulent Newcastle disease virus","volume":"184","author":"Sakaguchi","year":"1991","journal-title":"Virology"},{"key":"10.1038\/mt.2009.231_bib28","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/JVI.73.6.5001-5009.1999","article-title":"Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence","volume":"73","author":"Peeters","year":"1999","journal-title":"J Virol"},{"key":"10.1038\/mt.2009.231_bib29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1099\/vir.0.18714-0","article-title":"Effect of fusion protein cleavage site mutations on virulence of Newcastle disease virus: non-virulent cleavage site mutants revert to virulence after one passage in chicken brain","volume":"84","author":"de Leeuw","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1038\/mt.2009.231_bib30","doi-asserted-by":"crossref","first-page":"8203","DOI":"10.1073\/pnas.0602566103","article-title":"Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease","volume":"103","author":"Park","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2009.231_bib31","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/gt.2009.14","article-title":"Genetically engineered Newcastle disease virus for malignant melanoma therapy","volume":"16","author":"Zamarin","year":"2009","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2009.231_bib32","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1128\/JVI.02618-05","article-title":"Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines","volume":"80","author":"Krishnamurthy","year":"2006","journal-title":"J Virol"},{"key":"10.1038\/mt.2009.231_bib33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1006\/viro.1999.9983","article-title":"Impaired antiviral response in human hepatoma cells","volume":"263","author":"Keskinen","year":"1999","journal-title":"Virology"},{"key":"10.1038\/mt.2009.231_bib34","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/mt.2008.201","article-title":"Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3","volume":"16","author":"Marozin","year":"2008","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2009.231_bib35","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ymthe.2003.12.004","article-title":"Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus","volume":"9","author":"Shinozaki","year":"2004","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2009.231_bib36","first-page":"1492","article-title":"Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth","volume":"60","author":"Bateman","year":"2000","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2009.231_bib37","first-page":"356","article-title":"Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy","volume":"10","author":"Yun","year":"2008","journal-title":"Curr Opin Mol Ther"},{"key":"10.1038\/mt.2009.231_bib38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.cgt.7700071","article-title":"Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects","volume":"6","author":"Heise","year":"1999","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.2009.231_bib39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm0598-581","article-title":"Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression","volume":"4","author":"Melcher","year":"1998","journal-title":"Nat Med"},{"key":"10.1038\/mt.2009.231_bib40","first-page":"169","article-title":"Regulation of virus infections by natural killer cells. A review","volume":"5","author":"Welsh","year":"1986","journal-title":"Nat Immun Cell Growth Regul"},{"key":"10.1038\/mt.2009.231_bib41","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1128\/jvi.69.7.3967-3971.1995","article-title":"Major histocompatibility complex class I antigens and the control of viral infections by natural killer cells","volume":"69","author":"Brutkiewicz","year":"1995","journal-title":"J Virol"},{"key":"10.1038\/mt.2009.231_bib42","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ni1102-1006","article-title":"Viral evasion of natural killer cells","volume":"3","author":"Orange","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1038\/mt.2009.231_bib43","first-page":"1165","article-title":"Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice","volume":"118","author":"Liu","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2009.231_bib44","doi-asserted-by":"crossref","first-page":"8108","DOI":"10.1128\/JVI.00211-09","article-title":"Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase","volume":"83","author":"Jarahian","year":"2009","journal-title":"J Virol"},{"key":"10.1038\/mt.2009.231_bib45","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/hep.20536","article-title":"Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV","volume":"41","author":"Shinozaki","year":"2005","journal-title":"Hepatology"},{"key":"10.1038\/mt.2009.231_bib46","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/hep.22546","article-title":"Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats","volume":"48","author":"Altomonte","year":"2008","journal-title":"Hepatology"},{"key":"10.1038\/mt.2009.231_bib47","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V","article-title":"Newcastle disease virus as an Antineoplastic Agent","volume":"18","author":"Cassel","year":"1965","journal-title":"Cancer"},{"key":"10.1038\/mt.2009.231_bib48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1026392429112","article-title":"Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany","volume":"4","author":"Thasler","year":"2003","journal-title":"Cell Tissue Bank"},{"key":"10.1038\/mt.2009.231_bib49","doi-asserted-by":"crossref","first-page":"11868","DOI":"10.1128\/JVI.75.23.11868-11873.2001","article-title":"Recombinant Newcastle disease virus as a vaccine vector","volume":"75","author":"Nakaya","year":"2001","journal-title":"J Virol"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616316094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616316094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T03:29:03Z","timestamp":1657682943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616316094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S1525001616316094"],"URL":"https:\/\/doi.org\/10.1038\/mt.2009.231","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}